Institutional Ownership
Viridian Therapeutics Inc
CUSIP 92790C104COMVRDNQ1 2026
13D / 13G Filings
75
Schedule 13D/13G on record
Beneficial Filers
30
Distinct reporting persons
Largest Stake
20.0%
Max % of class reported
Institutional Holders
218
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
75 filings · latest Feb 17, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 17, 2026 | Kynam Capital Management, LP | 13G/A | 1.5% | 1.47M | SEC |
| 2 | Feb 13, 2026 | Deep Track Capital, LP | 13G/A | 2.6% | 2.52M | SEC |
| 3 | Nov 14, 2025 | Commodore Capital LP | 13G/A | 11.0% | 3.20M | SEC |
| 4 | Oct 27, 2025 | Fairmount Funds Management LLC | 13D/A | 15.1% | — | SEC |
| 5 | May 15, 2025 | Kynam Capital Management, LP | 13G | 5.8% | 4.70M | SEC |
| 6 | Apr 11, 2025 | Commodore Capital LP | 13G | 5.3% | 4.30M | SEC |
| 7 | Feb 14, 2025 | Venrock Healthcare Capital Partners III, L.P. | 13G/A | 4.5% | 3.58M | SEC |
| 8 | Nov 14, 2024 | Perceptive Advisors LLC | 13G/A | 3.8% | 2.81M | SEC |
| 9 | Nov 14, 2024 | Venrock Opportunities Fund, L.P. | 13G/A | 2.9% | 1.88M | SEC |
| 10 | Nov 14, 2024 | Venrock Healthcare Capital Partners III, L.P. | 13G/A | 5.5% | 3.58M | SEC |
65 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Viridian Therapeutics Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Fmr LLC | 15.38M | $300.82M |
| 2 | Blackrock, Inc. | 7.83M | $153.18M |
| 3 | Bellevue Group AG | 6.73M | $131.56M |
| 4 | State Street Corp | 4.67M | $91.40M |
| 5 | Fairmount Funds Management LLC | 3.91M | $76.57M |
| 6 | Venrock Adviser, LLC | 3.88M | $75.95M |
| 7 | Paradigm Biocapital Advisors LP | 3.15M | $61.59M |
| 8 | Wellington Management Group LLP | 3.08M | $60.22M |
| 9 | Kynam Capital Management, LP | 2.34M | $45.80M |
| 10 | Geode Capital Management, LLC | 2.33M | $45.65M |